Elicio Therapeutics
Develops AMP-enabled cancer immunotherapies centered on the ELI-002 mutant-KRAS program.
Something off on this page? Send us feedback.
Profile
Develops AMP-enabled cancer immunotherapies centered on ELI-002 for mutant-KRAS pancreatic and colorectal cancers. Its platform directs off-the-shelf immunotherapies to lymph nodes, alongside preclinical programs for mutant-BRAF and mutant-TP53 cancers.
Develops AMP-enabled cancer immunotherapies, with ELI-002 for mutant-KRAS pancreatic and colorectal cancers as the lead program. The Amphiphile platform is designed to carry payloads with albumin to lymph nodes, where it is intended to activate cancer-specific T-cell responses.
ELI-007 and ELI-008 are preclinical follow-on candidates targeting mutant-BRAF and mutant-TP53 cancers. Clinical development is concentrated in ELI-002, which is listed as a Phase 2 program.
The current ELTX security began Nasdaq trading after a 2023 reverse merger. Planned Phase 3 development and further AMP-platform work depend on financing and partnership support.
Company facts
Key statistics
Analysts
Target range
Latest analyst notes
| Date | Firm | Action | Prior rating | Rating | Target |
|---|---|---|---|---|---|
| Jun 16, 2026 | Jones Trading | Downgrade | Buy | Hold | |
| Mar 13, 2026 | H.C. Wainwright | Target | $17 | ||
| Mar 9, 2026 | C.L. King | Target | $17 |
Earnings
EPSReportedEstimate
RevenueReportedEstimate
Financials
Balance sheet, Jun 30, 2026Cash & short-term investments $23.5M · Total debt $14.1M · Total assets $31.3M · Shareholders' equity $7.9M
- Revenue
- $0
- Operating income
- −$10.4M
- Net income
- −$8.2M
Dividends
No dividends on record.
Ownership
| Institutions53 holders · as of Mar 31, 2026 | 13.85% | 2.64M shares | |
| Insiders6 holders · as of Feb 3, 2026 | 52.77% | 10.06M shares | |
| Strategic holders1 holder · as of Jul 16, 2026 | 7.39% | 1.41M shares | |
| Otherremainder | 25.99% | 4.96M shares |
19.07M company shares as of Aug 30, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Two share counts disagree (26.28M in the company's Sep 1, 2026 report, 19.07M elsewhere); stakes use the report.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Yekaterina Chudnovsky1Insiderdirector, 10 percent owner | 50.65% | 9.66M | 13Dfiled Mar 7, 2025 ↗ |
Moti Investments LLCStrategic | 7.39% | 1.41M | 13Gfiled Jul 16, 2026 ↗ |
Knoll Capital Management, LLCInstitution | 3.31% | 630,915 | 13Fas of Mar 31, 2026 |
Vanguard Capital Management LLCInstitution | 2.72% | 518,638 | 13Fas of Mar 31, 2026 |
Balyasny Asset Management L.P.Institution | 1.28% | 244,814 | 13Fas of Mar 31, 2026 |
| See all 25 → | |||
- Yekaterina Chudnovsky's transaction reports restate only vehicles that traded; the 2025 ownership statement (9.66M) is used instead.
13F — a manager's quarterly holdings · 13D/13G — an ownership statement filed at 5% or more
Insider tradesForm 4
No open-market trades in the last 12 months.
Peers
- Revolution Medicines
RAS inhibitor program spanning adjuvant and metastatic pancreatic cancer
- Bristol-Myers Squibb
Approved KRAS G12C targeted therapy for previously treated colorectal cancer
- Amgen
Approved KRAS G12C therapy and first-line colorectal-cancer trial
ComparePre-market
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Elicio Therapeutics | $2.80 | +3.51% | $51.5M | — | — | — | — |
| Revolution Medicines | $206.80 | +0.63% | $43.70B | — | — | — | — |
| Bristol-Myers Squibb | $66.86 | +0.09% | $136.47B | 14.7 | 10.5 | 2.8 | +5.7% |
| Amgen | $427.88 | −0.43% | $232.01B | 26.7 | 18.3 | 6.1 | +9.7% |
| Median | 20.7 | 14.4 | 4.4 | +7.7% |